FGH10019 exhibits numerous bioactivities, including significant inhibition of SREBP2 activation, which leads to the down-regulation of various genes involved in lipid metabolism such as stearoyl-CoA desaturase, MVK, HMG-CoA reductase, ATP citrate lyase, INSIG1, HMG-CoA synthase 1, isopentenyl diphosphate delta isomerase 1, and LDLR. The compound also exhibits antiobese activity in ob/ob C57BL/6J mice with positive effects on body weight, serum glucose, serum cholesterol, serum HDL and LDL levels, liver triglyceride levels, and a reduction in food intake. FGH10019 shows good aqueous solubility at both pH 3 and pH 7, favorable intrinsic clearance, acceptable half-life in mouse hepatocytes, and significant apparent permeability in PAMPA assays.
In addition, FGH10019 displays potent antimicrobial activity against various clinical isolates of Mycobacterium tuberculosis, including some resistant strains, with low inhibitory concentrations (MIC < 0.5 µg/mL) observed after 7 days of exposure. It demonstrates good solubility (1300.0 nM), low unbound fraction in mouse plasma (Fu < 0.01), and moderate intrinsic clearance in both mouse liver microsomes (CL = 28.84 mL.min-1.g-1) and human liver microsomes (CL = 4.3 mL.min-1.g-1).
Furthermore, in a luciferase reporter assay conducted in CHO-K1 cells, FGH10019 inhibits SREBP with an IC50 value of 700.0 nM..
Note: Summary generated by AI. Data source: ChEMBL 